Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Shigeoka, Y.
Right arrow Articles by Sasaki, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shigeoka, Y.
Right arrow Articles by Sasaki, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 31:370-374 (2001)
© 2001 Foundation for Promotion of Cancer Research

Clinical Effect of Irinotecan in Advanced and Metastatic Breast Cancer Patients Previously Treated with Doxorubicin- and Docetaxel-containing Regimens

Yasushi Shigeoka1, Kuniaki Itoh1, Tadahiko Igarashi1, Kenichi Ishizawa1, Toshiaki Saeki1, Hirofumi Fujii1, Hironobu Minami1, Shigeru Imoto2 and Yasutsuna Sasaki1,+

Division of 1Oncology/Hematology and 2Breast Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Background: Previous phase II trials in Japan suggested that irinotecan was a promising agent for advanced or metastatic breast cancer pretreated with anthracycline. However, irinotecan has not yet been evaluated in the salvage setting for breast cancer pretreated with both anthracycline and taxane, which are two active agents for breast cancer.

Methods: The efficacy and safety of irinotecan were retrospectively evaluated in patients with breast cancer who had previously been treated with both doxorubicin and docetaxel. From 1996 to 1999, irinotecan was administered to 20 patients, all with a performance status of <2. Irinotecan treatment was repeated in ~6 week cycles consisting of the administration of irinotecan once weekly for 4 weeks followed by a 2 week rest. The median dose of irinotecan administered was 100 mg/m2 weekly. The median number of irinotecan cycles given was 1 (range: 1–8 cycles). The median total dose was 388 mg/m2 (range: 50–2400 mg/m2).

Results: Performance status declined to >3 after treatment with irinotecan in four patients. Two patients had grade 3 leukopenia; three had grade 3 anemia and one had a creatinine elevation of grade 4. The objective response rate for all patients was 5.0% (95% CI: 0–15.5%). The median time to progression and overall survival were 35 days (range: 17–285 days) and 124 days (range: 17–667 days), respectively, since the start of the administration of irinotecan.

Conclusions: Salvage chemotherapy with irinotecan may be inactive against advanced and metastatic breast cancer pretreated with doxorubicin and docetaxel. We will evaluate irinotecan for advanced and metastatic breast cancer patients as first- or second-line chemotherapy combined with anthracycline or taxane.

+ For reprints and all correspondence: Kuniaki Itoh, Division of Oncology/Hematology, National Cancer Center Hospital East, 6–5–1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. E-mail address: kaito@east.ncc.go.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
E. A. Perez, D. W. Hillman, J. A. Mailliard, J. N. Ingle, J. M. Ryan, T. R. Fitch, K. M. Rowland, C. G. Kardinal, J. E. Krook, J. W. Kugler, et al.
Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or Both
J. Clin. Oncol., July 15, 2004; 22(14): 2849 - 2855.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.